OMASS TECHNOLOGIES
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
OMASS TECHNOLOGIES
Industry:
Life Science Pharmaceutical
Founded:
2016-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.omass.com
Total Employee:
11+
Status:
Active
Contact:
01865 548350
Email Addresses:
[email protected]
Total Funding:
118 M GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Microsoft Exchange Online Office 365 Mail GoDaddy DNS Google Google Maps API Google Cloud OpenResty
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Sentinel Oncology
Sentinel Oncology is a drug discovery company specialising in the delivery of candidate drugs to treat diseases.
XRnanotech
XRnanotech is a deep tech company that offers innovative nanostructured X-ray optics for high-tech applications.
Current Advisors List
Current Employees Featured
Founder
Investors List
GV
GV investment in Series B - OMass Technologies
Northpond Ventures
Northpond Ventures investment in Series B - OMass Technologies
Syncona Partners LLP
Syncona Partners LLP investment in Series B - OMass Technologies
Oxford Science Enterprises
Oxford Science Enterprises investment in Series B - OMass Technologies
Sanofi Ventures
Sanofi Ventures investment in Series B - OMass Technologies
Syncona Partners LLP
Syncona Partners LLP investment in Series A - OMass Technologies
Oxford Science Enterprises
Oxford Science Enterprises investment in Series A - OMass Technologies
Syncona Partners LLP
Syncona Partners LLP investment in Series A - OMass Technologies
Oxford Science Enterprises
Oxford Science Enterprises investment in Series A - OMass Technologies
Oxford Science Enterprises
Oxford Science Enterprises investment in Seed Round - OMass Technologies
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-15 | OMass Therapeutics Appoints Dr Jon Roffey as Vice President, Head of Medicinal Chemistry |
Official Site Inspections
http://www.omass.com Semrush global rank: 3.88 M Semrush visits lastest month: 3.31 K
- Host name: 300480.cloudwaysapps.com
- IP address: 178.62.119.83
- Location: London United Kingdom
- Latitude: 51.5353
- Longitude: -0.6658
- Timezone: Europe/London
- Postal: SL1
More informations about "OMass Technologies"
Team - Omass
He founded OMass and served as the first Chief Executive Officer, leading the company through its seed funding and series A financing rounds, allowing OMass to develop its own drug …See details»
About – Overview – Omass
At OMass Therapeutics, we are identifying new medicines against highly validated but inadequately drugged targets using novel biochemistry techniques, native mass spectrometry …See details»
OMass Therapeutics - Crunchbase Company Profile & Funding
Organization. OMass Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... OMass Therapeutics is a drug …See details»
OMass Therapeutics Announces New Phase of Growth with Move …
Apr 19, 2023 OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, that target solute carriers, complex-bound proteins, and GPCRs. …See details»
OMass Therapeutics: Creating groundbreaking …
The OMass platform’s proprietary biochemistry and patented mass spectrometry, along with the use of custom chemistry, mean that OMass can go after the best targets with greatly increased accuracy. This enables the company to design …See details»
OMass Establishes Scientific Advisory Board of Leading
Mar 7, 2022 OMass Therapeutics : Consilium Strategic Communications : Rosamond Deegan, Chief Executive Officer Phone: +44 (0) 1235 527589 Email: [email protected] Sue …See details»
OMass Therapeutics Raises $100 Million in Series B Financing to ...
Email: [email protected] Sue Charles / Chris Gardner / Kumail Waljee Phone: +44 (0)20 3709 5700 Email: [email protected] About OMass Therapeutics OMass …See details»
OMass Therapeutics Announces New Phase of Growth with Move …
Apr 19, 2023 PRESS RELEASE OMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio Progress Move to new …See details»
OMass Therapeutics Expands Leadership Team with Two New …
Aug 2, 2023 PRESS RELEASE OMass Therapeutics Expands Leadership Team with Two New Appointments Appointment of two senior executives in newly created rolesPeter Phillips M.D., …See details»
Working Here - Omass
People at OMass are open and enjoy a highly collaborative environment. We expect transparency from each other and from the company, and value information-sharing to keep our collective eyes on our overall goals. We are …See details»
OMass Therapeutics Expands Leadership Team with Two New …
Feb 8, 2023 Oxford, United Kingdom – 02 August 2023 – OMass Therapeutics (‘OMass’, or ‘the Company’), a biotechnology company that identifies medicines against highly validated target …See details»
OMass Therapeutics expands leadership team with the …
Nov 15, 2023 PRESS RELEASE OMass Therapeutics expands leadership team with the appointment of Melissa Faris as Chief Business Officer Oxford, United Kingdom – 15 …See details»
OMass Unveils Rich Drug Discovery Pipeline Targeting
Nov 4, 2021 OMass Therapeutics : Consilium Strategic Communications : Rosamond Deegan, Chief Executive Officer Phone: +44 (0) 1235 527589 Email: [email protected] Sue …See details»
OMass Therapeutics Expands Development Team with Key …
Oxford, United Kingdom – 1 October 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such …See details»
OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable …
Nov 4, 2021 PRESS RELEASE OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins Oxford, United …See details»
Oxford Mass Technologies - Providing A New Perspective in Drug ...
This video illustrates how the partnership between Thermo Fisher Scientific and OMass keeps OMass at the cutting edge of native mass spectrometry and provide...See details»
Science – Omass
OMass’ platform advantages. OMass’ platform retains biological relevance at high resolution, delivering cell-system fidelity with cell-free precision. Faithful to the native ecosystem. We use …See details»
OMass Unveils Rich Drug Discovery Pipeline Targeting ... - BioSpace
Oxford, United Kingdom – 4 November 2021– OMass Therapeutics (‘OMass’ or ‘the Company’), ... who joined as Chief Executive Officer in 2019 to aid the company’s transition to become a …See details»
In The News - Omass
Mar 11, 2024 Ros Deegan, CEO at OMass Therapeutics, Ltd, which develops new treatments using novel mass spectrometry approaches, also urged boldness (as well as canniness): …See details»